Lv1
12 积分 2023-02-13 加入
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study
5小时前
待确认
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias
1天前
已完结
Emerging drug profile: JAK inhibitors
4天前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
2个月前
已完结
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
2个月前
已完结
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist
3个月前
已完结
Therapeutic Effect of Blocking CXCR2 on Neutrophil Recruitment and Dextran Sodium Sulfate-Induced Colitis
4个月前
已完结
Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis
4个月前
已关闭
Prime editing for precise and highly versatile genome manipulation
5个月前
已完结
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden
5个月前
已完结
皖公网安备34019202002308
